0171U: Targeted genomic sequence analysis panel, acute myeloid leukemia, myelodysplastic syndrome, and myeloproliferative neoplasms, DNA analysis, 23 genes, interrogation for sequence variants, rearrangements and minimal residual disease, reported as presence/absence

Public Comment	**Rationale**
Gapfill	Though similar in properties to code 81450, the resources required to perform the testing are significantly different. LabPMM uses NGS to achieve more analytical sensitivity and we have standardized and increased the sensitivity of the assay for these mutations, which allows for detection of minimal residual disease.